{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:19:09Z","timestamp":1770545949119,"version":"3.49.0"},"reference-count":40,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.2967\/jnumed.120.246983","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:25:20Z","timestamp":1588987520000},"page":"81-87","source":"Crossref","is-referenced-by-count":36,"title":["The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study"],"prefix":"10.2967","volume":"62","author":[{"given":"Sara","family":"Harsini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Saprunoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Alden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnoud","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"2021051712154920000_62.1.81.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"2021051712154920000_62.1.81.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05798.x"},{"key":"2021051712154920000_62.1.81.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"2021051712154920000_62.1.81.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"2021051712154920000_62.1.81.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2021051712154920000_62.1.81.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"2021051712154920000_62.1.81.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2021051712154920000_62.1.81.8","first-page":"1445","article-title":"Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells","volume":"2","author":"Pinto","year":"1996","journal-title":"Clin Cancer Res."},{"key":"2021051712154920000_62.1.81.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.26"},{"key":"2021051712154920000_62.1.81.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2021051712154920000_62.1.81.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2021051712154920000_62.1.81.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2021051712154920000_62.1.81.13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and radionuclide therapy in prostate cancer","volume":"46","author":"Bouchelouche","year":"2016","journal-title":"Semin Nucl Med."},{"key":"2021051712154920000_62.1.81.14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712154920000_62.1.81.15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/molecules24030621","article-title":"Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: preliminary results of EUDRACT\/RSO 2016-002732-32 IRST protocol","volume":"24","author":"Sarnelli","year":"2019","journal-title":"Molecules."},{"key":"2021051712154920000_62.1.81.16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","article-title":"Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept","volume":"52","author":"Baum","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"key":"2021051712154920000_62.1.81.17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","article-title":"Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT","volume":"46","author":"Rathke","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712154920000_62.1.81.18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin Nucl Med."},{"key":"2021051712154920000_62.1.81.19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00259-017-3791-4","article-title":"Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results","volume":"44","author":"Matteucci","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712154920000_62.1.81.20","doi-asserted-by":"publisher","DOI":"10.1021\/jm950801q"},{"key":"2021051712154920000_62.1.81.21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics."},{"key":"2021051712154920000_62.1.81.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147181"},{"key":"2021051712154920000_62.1.81.23","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1021\/acs.jmedchem.6b00062","article-title":"Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA)","volume":"59","author":"Majer","year":"2016","journal-title":"J Med Chem."},{"key":"2021051712154920000_62.1.81.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215350"},{"key":"2021051712154920000_62.1.81.25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13550-016-0195-6","article-title":"Automated synthesis of [18F] DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models","volume":"6","author":"Bouvet","year":"2016","journal-title":"EJNMMI Res."},{"key":"2021051712154920000_62.1.81.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2021051712154920000_62.1.81.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186767"},{"key":"2021051712154920000_62.1.81.28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","article-title":"Current status of theranostics in prostate cancer","volume":"45","author":"Virgolini","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712154920000_62.1.81.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.226381"},{"key":"2021051712154920000_62.1.81.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170720"},{"key":"2021051712154920000_62.1.81.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.09.003"},{"key":"2021051712154920000_62.1.81.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.076174"},{"key":"2021051712154920000_62.1.81.33","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2021051712154920000_62.1.81.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"2021051712154920000_62.1.81.35","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate [abstract]","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med."},{"key":"2021051712154920000_62.1.81.36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40336-018-0270-2","article-title":"PSMA diagnostics and treatments of prostate cancer become mature","volume":"6","author":"von Eyben","year":"2018","journal-title":"Clin Transl Imaging."},{"key":"2021051712154920000_62.1.81.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1682"},{"key":"2021051712154920000_62.1.81.38","unstructured":"Nedelcovych MT Dash RP Wu Y . JHU-2545 selectively shields salivary glands and kidneys during PSMA-targeted radiotherapy. bioRxiv website. https:\/\/www.biorxiv.org\/content\/10.1101\/457085v1.full. Published October 30, 2020. Accessed July 23, 2020."},{"key":"2021051712154920000_62.1.81.39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/cbr.2019.3079","article-title":"Comparison of prostate-specific membrane antigen expression levels in human salivary glands to non-human primates and rodents","volume":"35","author":"Roy","year":"2020","journal-title":"Cancer Biother Radiopharm."},{"key":"2021051712154920000_62.1.81.40","first-page":"e04910","article-title":"Re\u2010evaluation of glutamic acid (E 620), sodium glutamate (E 621), potassium glutamate (E 622), calcium glutamate (E 623), ammonium glutamate (E 624) and magnesium glutamate (E 625) as food additives","volume":"15","author":"Mortensen","year":"2017","journal-title":"EFSA J."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.246983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:54:38Z","timestamp":1621284878000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.246983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.2967\/jnumed.120.246983"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.246983","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]}}}